Dr. Webster is best known for his research on HAL studies. His clinical research interests are diverse, including pain and pain mechanisms, substance abuse, sleep medicine, and cultural and political attitudes toward pain management. He earned his doctor of medicine from the University of Nebraska Medical Center and completed his residency at the University of Utah Medical Center’s department of anesthesiology.
Dr. Webster has authored numerous scientific abstracts and journal articles and lectures extensively. Recently, he released a book entitled, The Painful Truth: What Chronic Pain is Really Like and Why It Matters to Each of Us. A past president of the American Academy of Pain Medicine, he is currently the senior editor of its official journal, Pain Medicine. He also has a monthly column in Pain Medicine News and contributes regular articles and interviews to the press.

Before going to medical school, Dr. Searle attended Brigham Young University, majoring in Psychology with a pre-medicine emphasis. His medical training was at the University of Texas Health Science Center in San Antonio, TX. While completing his Medical Doctor Degree, he also participated in research with the orthopedic department examining the calcification processes of synovial and connective tissues. Dr. Searle then went to Phoenix, Arizona and completed his residency in Family Medicine at Banner Good Samaritan Hospital.
Dr. Searle began pharmaceutical research at Dedicated Phase One in Phoenix. He was Medical Director and Principal Investigator, and also on the company’s Board of Directors, for the first two years of the company’s existence and Dr. Searle helped it grow to be one of the premiere early-phase, patient-population sites in the Southwest. Study areas included Diabetes, Lupus, Alzheimer’s disease, Rheumatoid Arthritis, Multiple Sclerosis, Bipolar disorder and Healthy/Normal populations.
After a short time back in clinical medicine, Dr. Searle returned to early-phase research at Comprehensive Clinical Development in Tacoma, Washington. As Principal Investigator, his studies included First-In-Human trials as well as Oncology, Dermatology, Chronic Hepatitis C and Vaccine trials. He also certified and became licensed as an Authorized User of Radioactivity for the State of Washington. With this, he was the principal or sub-investigator for numerous trials examining the ADME (Absorption, Distribution, Metabolism and Excretion) and Pharmacokinetics of C 14 -labelled compounds in healthy/normal and Oncology patient populations.

He completed his first two years of medical school at the Universidad Autonoma de Guadalajara; where he acquired a solid foundation in clinical medicine and fluency in Spanish. He continued his education in Puerto Rico, and ultimately obtained his Medical Degree from Ponce School of Medicine.
After medical school, Dr. Sabet returned to the United States for continued training in Phoenix, Arizona. There he completed a dual residency in Internal Medicine and Pediatrics at Maricopa Medical Center, Phoenix Children’s Hospital, and the Mayo Clinic. He went on to become Chief Resident in Internal Medicine at Maricopa Medical Center during which he obtained his board certifications in both Internal Medicine and Pediatrics.
Following residency, Dr. Sabet embarked on a series of travel medicine assignments. He spent a year working as a consultant physician in New Zealand; after which he returned to work as an Internal Medicine hospitalist in several areas across the western United States. Ultimately he settled in Salt Lake City and after more than ten years of practicing and teaching clinical medicine, he found his way back to research.
Dr. Sabet joined PRA Health Sciences as a Sub-Investigator in September of 2015. His broad clinical experience has been well employed on trials across multiple disciplines including: pain/therapeutics, anesthesiology, immunology, lipid/metabolism, viral hepatitis, Alzheimer’s disease, and depression. His research experience includes First-In-Human, HAL, BE, VRH, and PK/PD trials in addition to multicenter phase II and III studies. He has quickly ascended through the research ranks and currently serves as Principal investigator on several early and late phase clinical trials.